Condition category
Digestive System
Date applied
17/10/2019
Date assigned
21/10/2019
Last edited
21/10/2019
Prospective/Retrospective
Retrospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
Sometimes people with severe acute pancreatitis can develop a complication where the pancreas loses its blood supply. This can cause some of the tissue of the pancreas to die (necrosis). When this happens, the pancreas can become infected, which can spread into the blood (sepsis) and cause organ failure. People with necrosis and an infection may need injections of antibiotics and surgery to remove the dead tissue. This is a very serious complication that needs treating, and it can be fatal. The study aims to compare standard treatment with a standard treatment preceded by fluid drainage immediately upon diagnosis.

Who can participate?
All adult patients admitted with a primary diagnosis of acute pancreatitis and persistent organ failure to one of the five participating hospitals of the Chinese Acute Pancreatitis Clinical Trials Group will be assessed for eligibility on a daily basis during their hospital stay.

What does the study involve?
Patients will be randomised to receive either immediate drainage followed by standard treatment, or standard treatment.

What are the possible benefits and risks of participating?
Participants can get some clinical benefit from the trial and some advice from doctors

Where is the study run from?
1. Jinling Hospital affiliated to Nanjing University (the lead center)
2. The First Affiliated Hospital of Nanchang University
3. Xiang Ya hospital Zhongnan University
4. Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine
5. Xijin Hospital, of the Fourth Military Medical University

When is the study starting and how long is it expected to run for?
March 2019 March 2022

Who is funding the study?
Jiangsu Province Key Research and Development Program (Social Development) Project

Who is the main contact?
1. Dr Qu Cheng
njumedqc@163.com
2. Dr Ke Lu
kkb9832@gmail.com

Trial website

Contact information

Type

Public

Primary contact

Mr Qu Cheng

ORCID ID

http://orcid.org/0000-0002-0822-5074

Contact details

305 Zhongshan Road East
Nanjing
210000
China
+8618862879105
njumedqc@163.com

Additional identifiers

EudraCT number

Nil known

ClinicalTrials.gov number

Nil known

Protocol/serial number

2018NZKY-009-04

Study information

Scientific title

Early on-demand intervention versus sTandard management among acute necrotIzing pancreatitis patients coMplicated by persIsteNt orGan failure: a multi-center randomized trial (TIMING trial)

Acronym

TIMING

Study hypothesis

Early percutaneous drainage in selected patients with acute necrotizing pancreatitis (ANC) and persistent organ failure (POF), who have aggravating or long-lasting organ failure during week 2-3 will result in improved clinical outcomes. We called this an on-demand approach for short. This will be tested in this randomized, controlled, multi-center study, aiming to compare the effect of the early on-demand intervention of ANC and standard treatment (delayed intervention)

Ethics approval

Approved 29/11/2018, Clinical trial ethics committee of the General Hospital of the Eastern Theater (305 Zhongshan Road East, Nanjing, Jiangsu, China; wuqiong80863234@163.com; +861 (0)25-80863234), ref: 2018NZKY-009-04

Study design

Multi-center randomized controlled open-label trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

No participant information sheet available

Condition

Acute pancreatitis

Intervention

This randomized, controlled, multi-center study, aims to compare the effect of the early on-demand intervention of ANC and standard treatment (delayed intervention)

Early intervention:
In addition to the standard treatment, ultrasound or CT guided percutaneous drainage would be applied within 24 hours once the patient is randomized to this group. At least one drainage catheter with size from 12F to 16F should be placed to drain the ANC, the content drained from the site will be tested by the standard procedure to detect potential infection (more drains are permitted). The treating physician is responsible for choosing the access routes, size and number of catheters.

Standard-treatment:
No intervention would be immediately applied if the participant is randomized to this group. Interventions including catheter drainage and necrosectomy would be delayed until suspicion or diagnosis of pancreatic infection and preferably after encapsulation of the necrotic collection (after four weeks for the best).

Patients will be randomly allocated to receive early intervention, within 24 hours after randomization, or standard treatment (delayed strategy) according to the current guidelines. Patients are randomized (1:1 ratio within each participating center and sample size of each center was predefined based on its volume) with a web-based randomization module (Interactive Web-Respond System (IWRS).

Intervention type

Behavioural

Phase

Drug names

Primary outcome measure

1. All-cause mortality in hospital
2. Major complications during the observational period

Secondary outcome measures

1. The fluctuation of organ functions reflected by the area under curve according to the revised Marshall score for seven consecutive days after randomization
2. Organ function assessed by revised Marshall at 14 and 21 days after randomization if available
3. Intraabdominal pressure for seven consecutive days after randomization and 14, 21 days after randomization if available
4. Incidence and timing of infected pancreatic necrosis
5. Incidence and timing of sepsis
6. Incidence and timing of other common complications such as abdominal bleeding and fistulas
7. Requirement of open surgery
8. ICU duration
9. Hospital duration
10. Total cost

Overall trial start date

01/06/2016

Overall trial end date

01/06/2022

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

Inclusion criteria for the screening period
Screening period starts from day 8 and extends to the end of the third week (day 21) consisting of 14 days:
1. Symptoms and signs of acute pancreatitis based on abdominal pain suggestive of AP, serum amylase at least three times the upper limit of normal, and/or characteristic findings of AP on computed tomography
2. Necrotic collection with available routes for ultrasound or CT guided percutaneous no matter sterile or infected
3. Confirmed persistent organ failure (either respiratory, renal or cardiovascular lasting for more than 48 hours), the organ failure score at day7 will be set as the baseline for the screening period
4. Age between 18 to 70 years old

Inclusion Criteria for randomization during screening period:
1. Patients in the screening period
2. Signs of deterioration from the baseline during the screening period including:
2.1. New-onset organ failure (no alleviation within 24 hours)
2.2. Unalleviated organ failure (either single or multiple, modified Marshall score≥2) lasting for at least seven days including the duration before the screening period
2.3. Aggravation of organ failure from the baseline (either single or multiple) evidence by increased modified Marshall score (no alleviation within 24 hours)

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

120

Participant exclusion criteria

1. Pregnant
2. Chronic pancreatitis, recurrent acute pancreatitis or pancreatic tumor-related pancreatitis
3. Percutaneous or transluminal drainage or surgery undertaken before admission
4. Previous history of cardio-pulmonary resuscitation
5. History of severe cardiovascular, respiratory, renal, hepatic, hematologic, or immunologic disease defined as:
5.1. Greater than New York Heart Association class II heart failure
5.2. Active myocardial ischemia
5.3. Cardiovascular intervention within the previous 60 days
5.4. History of cirrhosis
5.5 Chronic kidney disease with creatinine clearance< 40 mL/min
5.6 Chronic obstructive pulmonary disease with requirement for home oxygen

Recruitment start date

01/03/2019

Recruitment end date

01/03/2022

Locations

Countries of recruitment

China

Trial participating centre

Jinling Hospital affiliated to Nanjing University
305 Zhongshan Road East
Nanjing
210000
China

Trial participating centre

The First Affiliated Hospital of Nanchang University
17 Yongwaizheng street
Nanchang
330000
China

Trial participating centre

Xiang Ya hospital Zhongnan University
87 Xiangya Road
Changsha
410000
China

Trial participating centre

Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine
3 Qingchun East Road Jianggan District
Hangzhou
310000
China

Trial participating centre

Xijin Hospital of the Fourth Military Medical University
127 Changle West Road Xincheng District Xi'an City
Xian
710000
China

Sponsor information

Organisation

Department of science and technology of Jiangsu province

Sponsor details

39 East Beijing Road
Nanjing
210000
China
+861 (0)25 83350162
jjz_kj@js.gov.cn

Sponsor type

Government

Website

Funders

Funder type

Government

Funder name

Jiangsu Province Key Research and Development Program (Social Development) Project (BE2016749)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

IPD sharing statement:
All data generated or analysed during this study will be included in the subsequent results publication

Intention to publish date

01/06/2023

Participant level data

Other

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

21/10/2019: Trial’s existence confirmed by Clinical trial ethics committee of the General Hospital of the Eastern Theater